MX2022014768A - Anticuerpo multiespecifico. - Google Patents

Anticuerpo multiespecifico.

Info

Publication number
MX2022014768A
MX2022014768A MX2022014768A MX2022014768A MX2022014768A MX 2022014768 A MX2022014768 A MX 2022014768A MX 2022014768 A MX2022014768 A MX 2022014768A MX 2022014768 A MX2022014768 A MX 2022014768A MX 2022014768 A MX2022014768 A MX 2022014768A
Authority
MX
Mexico
Prior art keywords
multispecific antibody
antibody
msln
nucleic acid
acid sequence
Prior art date
Application number
MX2022014768A
Other languages
English (en)
Inventor
David Urech
Tea Gunde
Peter Lichtlen
Daniel Snell
Matthias Brock
Christian Hess
Alexandre Simonin
Stefan Warmuth
Bithi Chatterjee
Maria Johansson
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20177337.1A external-priority patent/EP3915580A1/en
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of MX2022014768A publication Critical patent/MX2022014768A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un anticuerpo multiespecífico que comprende dos dominios de unión basados en anticuerpo, que se unen específicamente a mesotelina (MSLN-BD); y al menos un dominio de unión basado en anticuerpo, que se une específicamente a CD3 (CD3-BD); en donde dicho anticuerpo multiespecífico no comprende un polipéptido de la región Fc de inmunoglobulina, y en donde cada uno de dichos MSLN-BD se une a mesotelina (MSLN) con una constante de disociación monovalente (KD) en el intervalo desde 0,5 hasta 20 nM, cuando se mide por SPR. La presente invención se refiere adicionalmente a secuencia(s) de ácidos nucleicos que codifica(n) dicho anticuerpo multiespecífico, vector(es) que comprende(n) dicha(s) secuencia(s) de ácidos nucleicos, célula(s) huésped que comprende(n) dicha(s) secuencia(s) de ácidos nucleicos o dicho(s) vector(es), y un procedimiento para producir dicho anticuerpo multiespecífico. Adicionalmente, la presente invención se refiere a composiciones farmacéuticas que comprenden dicho anticuerpo multiespecífico y procedimientos de uso de las mismas.
MX2022014768A 2020-05-29 2021-05-28 Anticuerpo multiespecifico. MX2022014768A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20177337.1A EP3915580A1 (en) 2020-05-29 2020-05-29 Multispecific antibody
PCT/EP2021/064427 WO2021239987A1 (en) 2020-05-29 2021-05-28 Multispecific antibody

Publications (1)

Publication Number Publication Date
MX2022014768A true MX2022014768A (es) 2023-01-11

Family

ID=84492160

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014768A MX2022014768A (es) 2020-05-29 2021-05-28 Anticuerpo multiespecifico.

Country Status (10)

Country Link
US (1) US20230203162A1 (es)
EP (1) EP4157352A1 (es)
JP (1) JP2023526976A (es)
KR (1) KR20230018397A (es)
CN (1) CN116134052A (es)
AU (1) AU2021278317A1 (es)
BR (1) BR112022024161A2 (es)
CA (1) CA3184899A1 (es)
IL (1) IL298076A (es)
MX (1) MX2022014768A (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7247110B2 (ja) * 2017-06-05 2023-03-28 ヌマブ セラピューティクス アクチェンゲゼルシャフト 新規抗ｃｄ３抗体

Also Published As

Publication number Publication date
EP4157352A1 (en) 2023-04-05
US20230203162A1 (en) 2023-06-29
AU2021278317A1 (en) 2022-12-22
CA3184899A1 (en) 2021-12-02
BR112022024161A2 (pt) 2023-02-07
CN116134052A (zh) 2023-05-16
IL298076A (en) 2023-01-01
JP2023526976A (ja) 2023-06-26
KR20230018397A (ko) 2023-02-07

Similar Documents

Publication Publication Date Title
JP2020511113A5 (es)
CY1122627T1 (el) Αντισωματα εναντι της ceacam6 και χρησεις αυτων
Štěpánová et al. Capillary electrophoretic methods applied to the investigation of peptide complexes
JP2020124209A5 (es)
RU2015111708A (ru) Способ получения и отбора молекул, включающих по меньшей мере две различные группировки и их применение
JP2011502522A5 (es)
RU2015100230A (ru) Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
CR20230309A (es) ANTICUERPOS MULTIESPECÍFICOS QUE TIENEN ESPECIFICIDAD PARA IL-4R e IL-31
JP2015502373A5 (es)
MX2022000652A (es) Anticuerpos contra claudina 18 y metodos de tratamiento del cancer.
IL177337A0 (en) Less immunogenic binding molecules
MX2022014768A (es) Anticuerpo multiespecifico.
MX2022011951A (es) Anticuerpos de la lectina 15 similar a la inmunoglobulina que se une a acido sialico (siglec15) y usos de los mismos.
RU2018137419A (ru) Связывающиеся с cd38 и pd-l1 молекулы
MX2022010665A (es) Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos.
WO2014144911A3 (en) Hybrid immunoglobulin containing non-peptidyl linkage
Jiang et al. Detection of cystatin C biomarker for clinical measurement of renal disease by developed ELISA diagnostic kits
MX2021014411A (es) Biomoleculas radiomarcadas con 18f.
WO2020238643A1 (zh) PETx聚合物、制备方法以及三维荆棘状传感器界面
ZA202304872B (en) Anti-sclerostin constructs and uses thereof
JP5412579B2 (ja) 速度因子
EP4019540A1 (en) Method for improving affinity of antibody for antigen and use thereof
JP2021506310A5 (es)
US20210403542A1 (en) alpha-SYNUCLEIN PROTOFIBRIL-BINDING ANTIBODIES
GB2596993A (en) Antibodies to symmetrically dimethylated arginine analytes and use thereof